Eikon Therapeutics

This study tests whether adding the experimental drug EIK1001 to the standard immunotherapy pembrolizumab helps people with advanced melanoma live longer without their cancer growing. About 740 adults with stage 3 or 4 melanoma that cannot be removed by surgery will receive eithe…

This study tests an experimental drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the combination can shrink tumors. About 160 adults with …

This study tests a new drug called EIK1001 combined with standard treatments (pembrolizumab and chemotherapy) in 70 people with stage 4 non-small cell lung cancer who haven't had prior treatment. The goal is to see if the combination is safe and shrinks tumors. Participants must …

This study tests a new drug called IMP1734 in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if it can shrink tumors or slow their growth. About 156 adults with certain types of breast, ovarian, or prostate c…